GLP-1 Drugs May Help Reduce Lung Scarring After COVID
12 Jul 20264 min read1 viewsVerified Feed
GIST (Key Takeaways)
Researchers from the University of Hong Kong investigated why people with type 2 diabetes are more likely to experience respiratory complications after COVID-19 and what can be done to prevent this. They discovered that inflammatory immune cells may contribute to lung scarring after a SARS-CoV-2 infection and that GLP-1 medications may offer protection.
According to the Centers for Disease Control and Prevention (CDC), about 1 in 8 people in the U.S. has diabetes, and type 2 diabetes makes up more than 90% of cases.
Doctors prescribe GLP-1 receptor agonists, including semaglutide and tirzepatide , to treat type 2 diabetes and obesity. Besides improving blood sugar control and promoting weight loss, these drugs may also reduce the risk of cardiovascular and kidney disease.
People with type 2 diabetes have a higher risk of developing long COVID and pulmonary fibrosis, a condition where scar tissue builds up in the lungs and makes breathing more difficult.
Clinical Editorial
Medical News Today published a clinical update in Research Highlights on 12 Jul 2026.
The item focuses on How GLP-1 drugs like Ozempic could help prevent lung scarring after COVID.
Review the original article for the full source wording and details.
Source Reference
Read the full original publication from the source journal or publisher link below.